The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).
J. O'Shaughnessy
Consultant or Advisory Role - Sanofi
L. S. Schwartzberg
Consultant or Advisory Role - Sanofi
M. A. Danso
No relevant relationships to disclose
H. S. Rugo
No relevant relationships to disclose
K. Miller
No relevant relationships to disclose
D. A. Yardley
No relevant relationships to disclose
R. W. Carlson
No relevant relationships to disclose
R. S. Finn
No relevant relationships to disclose
E. Charpentier
No relevant relationships to disclose
M. Freese
No relevant relationships to disclose
S. Gupta
No relevant relationships to disclose
A. Blackwood-Chirchir
No relevant relationships to disclose
E. P. Winer
No relevant relationships to disclose